The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022

With FDA filing on the horizon, Karuna appoints new CEO

Allergan alum Bill Meury will take the helm as current CEO Steve Paul transitions to lead R&D.

By Karissa Waddick • Dec. 9, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Takeda’s global quest for health equity

Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

By Taren Grom • Dec. 8, 2022

For Duchenne-focused Sarepta, gene therapy is the natural next step

The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

By Michael Gibney • Dec. 8, 2022

Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

By Taren Grom • Dec. 7, 2022

10 noteworthy pharma leadership shake-ups this year

From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

By Karissa Waddick • Dec. 7, 2022

Healthcare tech’s biggest busts

The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

By Taren Grom • Dec. 2, 2022

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

By Taren Grom • Nov. 30, 2022

One biotech’s approach to science-driven innovation

Why some in the industry say fostering creativity in drug development is all about work structures.

By Karissa Waddick • Nov. 29, 2022

5 enduring mysteries of the Barry and Honey Sherman murders

After nearly five years, the homicide case involving pharma billionaires continues to perplex investigators.

By Meagan Parrish • Nov. 28, 2022

Executive changes at Teva, Eversana could spell commercial growth in the new year

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Nov. 23, 2022

Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

Hybrid work is here to stay — here’s how leaders should adjust

Executives across the life sciences share their tips for navigating the new norm of remote work.

By Taren Grom • Nov. 18, 2022

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

By Taren Grom • Nov. 11, 2022

Woman of the Week: 82VS’s Trier Bryant

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

By Taren Grom • Nov. 9, 2022

Woman of the Week: City of Hope’s Gulden Mesara

Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

By Taren Grom • Nov. 2, 2022

Vaccine chief’s exit spurs new slate of GSK executive changes

How the pharma giant is consolidating power as it looks to become a dominant force in the vaccine market. 

By Karissa Waddick • Oct. 31, 2022

Pharma execs on creating a better workplace culture

Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

By Taren Grom • Oct. 28, 2022

What’s keeping pharma leaders up at night

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

By Taren Grom • Oct. 21, 2022

J&J reveals just how much economic turbulence is affecting Big Pharma

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

By Michael Gibney • Oct. 20, 2022

Woman of the Week: Exscientia’s Charlotte Deane

Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.

By Taren Grom • Oct. 19, 2022

He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

By Michael Gibney • Oct. 17, 2022

BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

What these life science organizations’ latest executive-level appointments mean for the industry.

By Karissa Waddick • Oct. 14, 2022

What’s your leadership brand?

Pharma industry leaders share their brand personas.

By Taren Grom • Oct. 14, 2022